These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38670590)

  • 1. Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.
    Sato K; Miura K; Tamori S; Akimoto K
    Cancer Genomics Proteomics; 2024; 21(3):316-326. PubMed ID: 38670590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
    Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
    Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
    O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L
    Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
    Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
    Front Immunol; 2021; 12():749459. PubMed ID: 34603338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
    Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
    Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC.
    Bao X; Shi R; Zhao T; Wang Y; Anastasov N; Rosemann M; Fang W
    Cancer Immunol Immunother; 2021 Jan; 70(1):189-202. PubMed ID: 32681241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
    Axelrod ML; Nixon MJ; Gonzalez-Ericsson PI; Bergman RE; Pilkinton MA; McDonnell WJ; Sanchez V; Opalenik SR; Loi S; Zhou J; Mackay S; Rexer BN; Abramson VG; Jansen VM; Mallal S; Donaldson J; Tolaney SM; Krop IE; Garrido-Castro AC; Marotti JD; Shee K; Miller TW; Sanders ME; Mayer IA; Salgado R; Balko JM
    Clin Cancer Res; 2020 Nov; 26(21):5668-5681. PubMed ID: 32826327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments.
    Zhang M; Zhang F; Wang J; Liang Q; Zhou W; Liu J
    J Transl Med; 2024 May; 22(1):423. PubMed ID: 38704606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LCP1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer.
    Pan S; Wan M; Jin H; Ning R; Zhang J; Han X
    BMC Immunol; 2024 Jul; 25(1):42. PubMed ID: 38977952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer.
    Cai P; Lu Z; Wu J; Qin X; Wang Z; Zhang Z; Zheng L; Zhao J
    J Cell Biochem; 2020 Mar; 121(3):2643-2654. PubMed ID: 31692043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
    Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
    World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature.
    Qin Y; Deng J; Zhang L; Yuan J; Yang H; Li Q
    Aging (Albany NY); 2021 Feb; 13(4):5485-5505. PubMed ID: 33536349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of tumor immune infiltration and prognosis with homologous recombination repair genes mutations in early triple-negative breast cancer.
    Wang Z; Li A; Lu Y; Han M; Ruan M; Wang C; Zhang X; Zhu C; Shen K; Dong L; Chen X
    Front Immunol; 2024; 15():1407837. PubMed ID: 39026672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating machine learning algorithms and multiple immunohistochemistry validation to unveil novel diagnostic markers based on costimulatory molecules for predicting immune microenvironment status in triple-negative breast cancer.
    Zhang C; Zhai W; Ma Y; Wu M; Cai Q; Huang J; Zhou Z; Duan F
    Front Immunol; 2024; 15():1424259. PubMed ID: 39007147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
    Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
    Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
    Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
    Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.